Answers are grounded in this paper and cite their sources.
Nanobodies (Nbs) offer attractive properties for small-analyte immunodetection, but their use remains largely restricted to competitive formats because small analytes cannot ordinarily bind two antibodies simultaneously. Anti-immunocomplex (anti-IC) reagents enable noncompetitive assays with direct positive readouts but are difficult to generate, as analyte binding modifies only a restricted region of the capture antibody and often produces reagents that cross-react with the unliganded antibody. Here, we combined enhanced IC immunogenicity with competitive phage-display selection to isolate an anti-IC Nb for microcystin-LR (MC-LR). The anti-MC Nb A2 was fused to human Fc, saturated with MC-LR, and used for immunization. Selection against the A2-MC-LR IC in the presence of excess unliganded A2 yielded K3, a rare IC-selective Nb. K3 showed no detectable binding to free MC-LR and only weak binding to unliganded A2 at high concentrations while binding the IC with a KD of 10.5 nM. Combining K3 with oriented immobilization of biotinylated A2 produced a noncompetitive ELISA with an SC50 of 0.308 μg/L and a theoretical LOQ of 0.074 μg/L. Across diverse water matrices, recoveries were 85−126% at 0.5 μg/L, with useful quantitative estimates also obtained at 0.1 μg/L. Results from 12 reservoir-water samples showed a good overall agreement with quantitative MALDI-TOF. The assay showed more balanced cross-reactivity toward common MC congeners than the A2-based competitive format. To our knowledge, this is the first strategy combining enhanced IC immunogenicity and competitive phage-display selection to isolate anti-IC Nbs for noncompetitive detection of small analytes. Such compact, genetically engineerable binders could facilitate miniaturized and in situ noncompetitive immunosensing.
No takes yet. Share an insight, caveat, or question.
Santos et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: